Navigation Links
LifeMasters Offers Financial Incentives to Florida Physicians for Participation in Disease Management Programs
Date:1/29/2009

Contracts with Health Network One, Inc. of Hallandale, FL

Irvine, CA (Vocus) January 29, 2008 -- In an effort to further integrate physicians into large- scale health improvement programs in a meaningful way, LifeMasters Supported SelfCare, Inc. has contracted with a provider network to increase physician support for its demonstration project targeting Medicare and Medicaid recipients in South Florida.

A national provider of health improvement services, LifeMasters is working with the Centers for Medicare & Medicaid Services (CMS) on a demonstration project in multiple counties designed to measure the effectiveness of a disease management program in a Medicare fee-for-service population. The program is available to beneficiaries who are eligible for both Medicare and Medicaid and who have congestive heart failure (CHF) or any combination of CHF, diabetes and coronary artery disease. Physician engagement in disease management is a priority for CMS, especially in the fee-for-service population since care for these individuals is often fragmented and lacks coordination.

LifeMasters has contracted with the provider network Health Network One, Inc (HN1) of Hallandale, Fla. to provide financial incentives to physicians to encourage their patients to actively participate in the LifeMasters program. Physicians receive a per-member per-month fee for each patient engaged in the program, with incremental increases the longer the participant remains in the program.

"LifeMasters has always strongly supported the physician-patient relationship through our programs. We provide real time, actionable patient data to physicians through our Health Alerts, which recent research has shown enables them make data-driven adjustments in their treatment plan," said Christobel Selecky, CEO of LifeMasters. "We are now extending our relationship with physicians by givi
'/>"/>

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

0

GOOD

Page: 1 2 3

Related medicine news :

1. LifeMasters Provides Tips for Maintaining a Healthy Blood Cholesterol Level
2. Charles A. Peck, M.D., F.A.C.P. Joins LifeMasters as New Medical Director Focused on Client Experience
3. LifeMasters Receives Full URAC Disease Management Accreditation
4. The Centers for Medicare & Medicaid Services Extends LifeMasters Demonstration Project in Florida
5. LifeMasters Strengthens Capital Structure with $15 Million in Funding from Existing Investors
6. LifeMasters Announces Agreement to Offer Disease Management Services to High-Risk Wisconsin Residents
7. LifeMasters Receives 2008 Vision Award for Business Impact
8. LifeMasters Receives Full Accreditation for Disease Management Programs
9. Research Shows Successful Physician Engagement in LifeMasters Disease Management Programs
10. Health care incentive model offers collaborative approach
11. Eye-staining technique offers early detection for dry eye syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
LifeMasters Offers Financial Incentives to Florida Physicians for Participation in Disease Management Programs 
LifeMasters Offers Financial Incentives to Florida Physicians for Participation in Disease Management Programs
Other Medicine News:Health News:Secretary Shinseki Announces $215 Million in Projects for Rural Veterans 2Health News:FDA Approves SAMSCA(TM) (tolvaptan), the First and Only Oral Vasopressin Antagonist to Treat Patients With Clinically Significant Hypervolemic and Euvolemic Hyponatremia 2Health News:FDA Approves SAMSCA(TM) (tolvaptan), the First and Only Oral Vasopressin Antagonist to Treat Patients With Clinically Significant Hypervolemic and Euvolemic Hyponatremia 3Health News:FDA Approves SAMSCA(TM) (tolvaptan), the First and Only Oral Vasopressin Antagonist to Treat Patients With Clinically Significant Hypervolemic and Euvolemic Hyponatremia 4Health News:FDA Approves SAMSCA(TM) (tolvaptan), the First and Only Oral Vasopressin Antagonist to Treat Patients With Clinically Significant Hypervolemic and Euvolemic Hyponatremia 5Health News:FDA Approves SAMSCA(TM) (tolvaptan), the First and Only Oral Vasopressin Antagonist to Treat Patients With Clinically Significant Hypervolemic and Euvolemic Hyponatremia 6Health News:FDA Approves SAMSCA(TM) (tolvaptan), the First and Only Oral Vasopressin Antagonist to Treat Patients With Clinically Significant Hypervolemic and Euvolemic Hyponatremia 7Health News:FDA Approves SAMSCA(TM) (tolvaptan), the First and Only Oral Vasopressin Antagonist to Treat Patients With Clinically Significant Hypervolemic and Euvolemic Hyponatremia 8Health News:FDA Approves SAMSCA(TM) (tolvaptan), the First and Only Oral Vasopressin Antagonist to Treat Patients With Clinically Significant Hypervolemic and Euvolemic Hyponatremia 9Health News:Blue Cross and Blue Shield of Georgia and Piedmont Healthcare Announce Contract Renewal 2Health News:Thousands of Canada's best minds converge at Congress 2009 2Health News:Beazley's New Management Liability Coverage is Tailored to Unique Needs of Healthcare Organizations 2Health News:Beazley's New Management Liability Coverage is Tailored to Unique Needs of Healthcare Organizations 3Health News:Study: Lower Legal Drinking Age Increases Poor Birth Outcomes 2Health News:Study: Lower Legal Drinking Age Increases Poor Birth Outcomes 3
Breaking Medicine Technology:FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 2FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 3FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 5Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 6Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 7Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 8Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 9Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 10Childrens Hospitals and Clinics of Minnesota Receives National Recognition for Quality and Efficiency 62578 1Childrens Hospitals and Clinics of Minnesota Receives National Recognition for Quality and Efficiency 62578 2Settlement in AMA Lawsuit against UnitedHealth Gets Preliminary Approval from Federal Court 62575 1Settlement in AMA Lawsuit against UnitedHealth Gets Preliminary Approval from Federal Court 62575 2VIDEO from Medialink and the American Nurses Association 28ANA 29 3A American Nurses Association Urges All Americans to Take Part in Health Care Refo 62572 1VIDEO from Medialink and the American Nurses Association 28ANA 29 3A American Nurses Association Urges All Americans to Take Part in Health Care Refo 62572 2